TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Clinical trial NCT07487662 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07487662
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-18
- Primary completion
- 2028-03-17
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.